Calliditas: Comfortably ahead - Redeye

We have taken a sceptical view regarding the potential threat from Sparsentan (Travere Therapeutics) ahead of additional long-term data from more extensive studies regardless of an early (premature) approval or not. Hence we are not highlighting the impact of the recent delayed Sparsentan PDUFA date.

Länk till analysen i sin helhet: https://www.redeye.se/research/858250/calliditas-comfortably-ahead?utm_source=finwire&utm_medium=RSS